Journals / Dicle Tıp Dergisi / 2022 / Cilt: 49 Sayı: 3

Retrospective Comparison of Chemotherapy Plus Anti-HER2 Therapies at First-line Treatment in Patients with Metastatic Gastric Adenocarcinoma

Fatih Gurler(UNIVERSITY OF HEALTH SCIENCES, ANKARA KEÇİÖREN EDUCATION AND RESEARCH HOSPITAL)
Aysegul İlhan Gulesen(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA DR. ABDURRAHMAN YURTASLAN ONKOLOJİ SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)
Berna Oksuzoglu(UNIVERSITY OF HEALTH SCIENCES, ANKARA KEÇİÖREN EDUCATION AND RESEARCH HOSPITAL)
Pages
468–476
Publication Date
2022-09-02
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: It was revealed that CF-T and mFOLFOX6-T had similar efficacy and tolerability in patients with HER2-positive metastatic gastric adenocarcinoma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: We aimed to compare the efficacy and the safety of cisplatin plus 5-FU plus trastuzumab and mFOLFOX-6 plus trastuzumab at first-line treatment in HER2-positive metastatic gastric cancer.
📊
Key Findings & Data:Patients diagnosed with HER2-positive metastatic gastric adenocarcinoma between January 2013 and December 2020 in Dr AY Ankara Oncology TRH were screened.
💡
Conclusion & Impact:Conclusion: It was revealed that CF-T and mFOLFOX6-T had similar efficacy and tolerability in patients with HER2-positive metastatic gastric adenocarcinoma.
🔬Design:Araştırma Makalesi
📍Scope:2013 Verileri
⚙️Variables:metastatic gastric cancer · anti-HER2 · FOLFOX

Abstract

Aim: We aimed to compare the efficacy and the safety of cisplatin plus 5-FU plus trastuzumab and mFOLFOX-6 plus trastuzumab at first-line treatment in HER2-positive metastatic gastric cancer. Method: It was a retrospective observational monocentric study. Patients diagnosed with HER2-positive metastatic gastric adenocarcinoma between January 2013 and December 2020 in Dr AY Ankara Oncology TRH were screened. Patients treated at least one cycle of treatment with either CF-T or mFOLFOX-T were included. Survival outcomes and treatment compliance of patients were compared between groups. Results: Of 52 patients, 55.8% (n=29) of patients were treated with CF-T, and 44.2% (n=23) with mFOLFOX-T. The median age at diagnosis was 60 years (IQR: 52-70) in the CF-T and 64 years (IQR: 59-70) in the mFOLFOX-T groups. De novo metastatic disease comprised 96.6% (n=28) of patients in the CF-T and 69.6% (n=16) in the mFOLFOX-T groups (p=0.016). Both IHC3+ and ISH positivity were observed 82.8% (n=24) of patients in the CF-T and 56.5% (n=13) in mFOLFOX-T groups (p=0.038). The mPFS was 10.4 months (95% CI 8.7-12.2) in the CF-T and 6.5 months (95% CI 5.5-7.6) in the mFOLFOX-T groups (p=0.532). The mOS was 12.2 months (95% CI 11.3-13.2) in the CF-T and 12.5 months (95% CI 9.8-15.5) in the mFOLFOX-T groups (p=0.974). No statistically significant difference regarding at least one dose reduction (31.0% vs 21.7%, p=0.453) and at least one dose delay (24.1% vs 21.7%, p=0.838) was observed between groups. Conclusion: It was revealed that CF-T and mFOLFOX6-T had similar efficacy and tolerability in patients with HER2-positive metastatic gastric adenocarcinoma.

🔖

Cite This Article

Gurler, F., Gulesen, A. İ., Oksuzoglu, B. (2022). Retrospective Comparison of Chemotherapy Plus Anti-HER2 Therapies at First-line Treatment in Patients with Metastatic Gastric Adenocarcinoma. Dicle Tıp Dergisi, Cilt: 49 Sayı: 3, 468–476. https://doi.org/10.5798/dicletip.1170175

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Sung H, Ferlay J, Siegel RL, et al. Global cancerstatistics 2020: GLOBOCAN estimates of incidenceand mortality worldwide for 36 cancers in 185countries. CA Cancer J Clin. 2021;71:209-49.
  2. Bass AJ, Thorsson V, Shmulevich I, et al.Comprehensive molecular characterization ofgastric adenocarcinoma. Nature. 2014;513:202.
  3. Van Cutsem E, Bang Y-J, Feng-Yi F, et al. HER2screening data from ToGA: targeting HER2 in gastricand gastroesophageal junction cancer. Gastriccancer. 2015;18:476-84.
  4. NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines®) Gastric Cancer Version 2.2022— January 11, 2022 (https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf).
  5. Bang Y-J, Van Cutsem E, Feyereislova A, et al.Trastuzumab in combination with chemotherapyversus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophagealjunction cancer (ToGA): a phase 3, open-label,randomised controlled trial. Lancet. 2010;376:687-97.